HPRA Drug Safety Newsletter Edition 98
Download:
hpra-drug-safety-issue-number-98.pdf
436 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
- Adverse reaction reporting during the COVID-19 pandemic – reminder
- Picato (ingenol mebutate) – EMA review concludes negative benefit risk balance due to risk of skin malignancy
- Levetiracetam – risk of abnormal and aggressive behaviours
- Cyproterone acetate – restrictions in use due to risk of meningioma
- Carbimazole and propylthiouracil – use in pregnancy and in women of childbearing potential
- Carbimazole – risk of acute pancreatitis
- Testosterone-containing medicinal products: caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE)
« Back